PTC Therapeutics (PTCT) – Investment Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of PTC Therapeutics (NASDAQ: PTCT) in the last few weeks:

• 1/8/2026 – PTC Therapeutics had its “overweight” rating reaffirmed by analysts at Morgan Stanley. They now have a $90.00 price target on the stock.
• 1/3/2026 – PTC Therapeutics was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 12/29/2025 – PTC Therapeutics had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – PTC Therapeutics had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – PTC Therapeutics had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – PTC Therapeutics had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/6/2025 – PTC Therapeutics was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 12/1/2025 – PTC Therapeutics had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – PTC Therapeutics was downgraded by analysts at Royal Bank Of Canada from an “outperform” rating to a “sector perform” rating. They now have a $91.00 price target on the stock, up previously from $82.00.
• 11/25/2025 – PTC Therapeutics had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – PTC Therapeutics had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – PTC Therapeutics had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.

Insiders Place Their Bets

In other PTC Therapeutics news, insider Eric Pauwels sold 40,290 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $75.43, for a total value of $3,039,074.70. Following the completion of the transaction, the insider directly owned 70,373 shares in the company, valued at $5,308,235.39. This trade represents a 36.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Allan Steven Jacobson sold 14,199 shares of PTC Therapeutics stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $83.55, for a total transaction of $1,186,326.45. Following the completion of the transaction, the director directly owned 17,451 shares in the company, valued at approximately $1,458,031.05. This trade represents a 44.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 287,633 shares of company stock worth $22,674,765 over the last three months. Company insiders own 5.50% of the company’s stock.

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.